N-(2-(4-Methoxybenzoyl)phenyl)-2-(3-m-tolylureido)acetamide | 171725-29-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-(4-Methoxybenzoyl)phenyl)-2-(3-m-tolylureido)acetamide
• 英文别名: N-[2-(4-methoxybenzoyl)phenyl]-2-[(3-methylphenyl)carbamoylamino]acetamide
• CAS: 171725-29-4
• 化学式: C₂₄H₂₃N₃O₄
• 分子量: 417.464
• InChiKey: DLAOSCXZARXNRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  96.5
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  溴乙酸叔丁酯 、 N-(2-(4-Methoxybenzoyl)phenyl)-2-(3-m-tolylureido)acetamide 在 potassium carbonate 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-anisyl-2-{N-(tert-butoxycarbonylmethyl)-N-[N'-(m-tolyl)ureidomethylcarbonyl]amino}phenylketone
  参考文献：
  名称：

  Synthesis and pharmacological properties of ureidomethylcarbamoylphenylketone derivatives. A new potent and subtype-selective nonpeptide CCK-B/gastrin receptor antagonist, S-0509

  摘要：

  A novel series of CCK-B/gastrin receptor antagonists-ureidomethylcarbamoylphenylketone derivatives were designed, synthesized, and evaluated for activity. Structure-activity relationship studies revealed the importance of a carboxylic acid at substituent R-2 and a tert-butoxycarbonyl group at R-1 in structure A. Compound 7a (S-0509) showed remarkable affinity for the CCK-B/gastrin receptor and a subtype selectivity profile in vitro. Administration (id) of 7a led to excellent inhibition of gastric acid secretion induced by pentagastrin in anesthetized rats with an ED50 value of 0.014 mg/kg. Furthermore, 7a proved to have poor blood-brain permeability by its small effect on enhancement of morphine analgesia. Thus, S-0509 has an increase in selectivity for the peripheral effects of gastrin antagonism from the central effects of CCK-B antagonism. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00104-1
• 作为产物：
  描述：

  4-anisyl-[2-(N-Cbz-glycylamino)phenyl]ketone 在 氢溴酸 、 溶剂黄146 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 N-(2-(4-Methoxybenzoyl)phenyl)-2-(3-m-tolylureido)acetamide
  参考文献：
  名称：

  Synthesis and pharmacological properties of ureidomethylcarbamoylphenylketone derivatives. A new potent and subtype-selective nonpeptide CCK-B/gastrin receptor antagonist, S-0509

  摘要：

  A novel series of CCK-B/gastrin receptor antagonists-ureidomethylcarbamoylphenylketone derivatives were designed, synthesized, and evaluated for activity. Structure-activity relationship studies revealed the importance of a carboxylic acid at substituent R-2 and a tert-butoxycarbonyl group at R-1 in structure A. Compound 7a (S-0509) showed remarkable affinity for the CCK-B/gastrin receptor and a subtype selectivity profile in vitro. Administration (id) of 7a led to excellent inhibition of gastric acid secretion induced by pentagastrin in anesthetized rats with an ED50 value of 0.014 mg/kg. Furthermore, 7a proved to have poor blood-brain permeability by its small effect on enhancement of morphine analgesia. Thus, S-0509 has an increase in selectivity for the peripheral effects of gastrin antagonism from the central effects of CCK-B antagonism. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00104-1

文献信息

• Carbamoylmethylurea derivatives
  申请人：Shionogi & Co., Ltd.

  公开号：US05739162A1

  公开（公告）日：1998-04-14

  A compound of the formula (I): ##STR1## wherein R.sub.1 is a hydrogen atom or lower alkyl; R.sub.2 is a lower alkoxy, lower alkylamino, lower cycloalkyl, optionally substituted phenyl or optionally substituted heterocyclic group; R.sub.3 is an optionally substituted phenyl; R.sub.4 is an optionally substituted phenyl, optionally substituted cycloalkyl, optionally substituted alkyl or optionally substituted heterocyclic group, or a pharmaceutically acceptable salt thereof, which has a high affinity for gastrin receptors and/or CCK-B receptors but not for CCK-A receptors, and is useful for treating diseases associated with gastrin receptors and/or CCK-B receptors without inducing the side effects associated with CCK-A receptors.

  化合物的式子(I)：##STR1## 其中，R.sub.1是氢原子或低烷基；R.sub.2是低烷氧基、低烷基氨基、低环烷基、可选取代的苯基或可选取代的杂环基；R.sub.3是可选取代的苯基；R.sub.4是可选取代的苯基、可选取代的环烷基、可选取代的烷基或可选取代的杂环基，或其药学上可接受的盐。该化合物具有高亲和力的胃泌素受体和/或CCK-B受体，但不具有CCK-A受体的亲和力。它可用于治疗与胃泌素受体和/或CCK-B受体相关的疾病，而不会引起与CCK-A受体相关的副作用。
• CARBAMOYLMETHYLUREA DERIVATIVE
  申请人：SHIONOGI & CO., LTD.

  公开号：EP0739903B1

  公开（公告）日：2002-01-23
• US5739162A
  申请人：——

  公开号：US5739162A

  公开（公告）日：1998-04-14